A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation

European Journal of Cancer

Volumn 49, Issue 13, 2013, Pages 2832-2840

  Inaba, Yoshitaka ^a   Kanai, Fumihiko ^b   Aramaki, Takeshi ^c   Yamamoto, Takanobu ^d   Tanaka, Toshihiro ^e   Yamakado, Koichiro ^f   Kaneko, Shuichi ^g   Kudo, Masatoshi ^h   Imanaka, Kazuho ⁱ   Kora, Shinichi ^j   Nishida, Norifumi ^k   Kawai, Nobuyuki ^l   Seki, Hiroshi ^m   Matsui, Osamu ^g   Arioka, Hitoshi ⁿ   Arai, Yasuaki ^o  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d TOCHIGI CANCER CENTER   (Japan)

^e NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^f MIE UNIVERSITY HOSPITAL   (Japan)

^g KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^h KINDAI UNIVERSITY HOSPITAL   (Japan)

ⁱ OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^j FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^k OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

^l WAKAYAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^m NIIGATA CANCER CENTER HOSPITAL   (Japan)

ⁿ YOKOHAMA ROSAI HOSPITAL   (Japan)

^o NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

factor; Hepatocellular carcinoma; Platelet derived growth; Transarterial chemoembolisation; TSU 68

Indexed keywords

ORANTINIB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; CANCER PATIENT; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; LIVER CELL CARCINOMA; LIVER FAILURE; MALE; MELENA; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA;

HEPATOCELLULAR CARCINOMA; PLATELET-DERIVED GROWTH FACTOR; TRANSARTERIAL CHEMOEMBOLISATION; TSU-68;

AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPIONATES; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84881104603     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.05.011     Document Type: Article

References (34)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. M.C. Kew Prevention of hepatocellular carcinoma Ann Hepatol 9 2010 120 132
3. E. Fassio, and C. Hepatitis And hepatocellular carcinoma Ann Hepatol 9 Suppl. 2010 119 122
4. M. Levrero Viral hepatitis and liver cancer: the case of hepatitis C Oncogene 25 2006 3834 3847
5. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
6. A.L. Cheng, Y.K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
7. J.M. Llovet, M.I. Real, and X. Montana Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
8. C.M. Lo, H. Ngan, and W.K. Tso Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
9. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
10. A.D. Laird, P. Vajkoczy, and L.K. Shawver SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors Cancer Res 60 2000 4152 4160
11. C.C. Solorzano, Y.D. Jung, and C.D. Bucana In vivo intracellular signaling as a marker of antiangiogenic activity Cancer Res 61 2001 7048 7051
12. B.C. Kuenen, G. Giaccone, and R. Ruijter Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies Clin Cancer Res 11 2005 6240 6246
13. K. Yorozuya, T. Kubota, and M. Watanabe TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis Oncol Rep 14 2005 677 682
14. E. Naumova, P. Ubezio, and A. Garofalo The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis Clin Cancer Res 12 2006 1839 1849
15. F. Kanai, H. Yoshida, and R. Tateishi A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma Cancer Chemother Pharmacol 67 2011 315 324
16. R. Lenchioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
17. R. Gillmore, S. Stuart, and A. Kirkwood EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 55 2011 1309 1316
18. S. Ueno, G. Tanabe, and K. Nuruki Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis Hepatol Res 24 2002 395 403
19. J.M. Llovet, C. Bru, and J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
20. M.B. Thomas, D. Jaffe, and M.M. Choti Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting J Clin Oncol 28 2010 3994 4005
21. J. Meza-Junco, A.J. Montano-Loza, and D.M. Liu Locoregional radiological treatment for hepatocellular carcinoma; which, when and how? Cancer Treat Rev 38 2012 54 62
22. S. Faivre, E. Raymond, and E. Boucher Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Lancet Oncol 10 2009 794 800
23. M. Kudo, K. Imanaka, and N. Chida Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma Eur J Cancer 47 2011 2117 2127
24. A. Sergio, C. Cristofori, and R. Cardin Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness Am J Gastroenterol 103 2008 914 921
25. H. Suzuki, M. Mori, C. Kawaguchi, M. Adachi, S. Miura, and H. Ishii Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma Int J Oncol 14 1999 1087 1090
26. X. Li, G.S. Feng, C.S. Zheng, C.K. Zhuo, and X. Liu Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level World J Gastroenterol 10 2004 2878 2882
27. R.T. Poon, C. Lau, W.C. Yu, S.T. Fan, and J. Wong High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study Oncol Rep 11 2004 1077 1084
28. M. Fuksiewicz, M. Kowalska, and B. Kotowicz Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer Clin Chem Lab Med 48 2010 1481 1486
29. Y. Okugawa, C. Miki, Y. Toiyama, Y. Koike, Y. Inoue, and M. Kusunoki Serum level of soluble vascular cell adhesion molecule 1 is a valuable prognostic marker in colorectal carcinoma Dis Colon Rectum 52 2009 1330 1336
30. J.M. Roodhart, M.H. Langenberg, E. Witteveen, and E.E. Voest The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway Curr Clin Pharmacol 3 2008 132 143
31. T. Zhang, H.C. Sun, and Y. Xu Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential Clin Cancer Res 11 2005 8557 8563
32. D.M. O'Hanlon, H. Fitzsimons, J. Lynch, S. Tormey, C. Malone, and H.F. Given Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma Eur J Cancer 38 2002 2252 2257
33. D. Alexiou, A.J. Karayiannakis, and K.N. Syrigos Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients Am J Gastroenterol 98 2003 478 485
34. M. Raica, and A.M. Cinpean Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy Pharmaceuticals 3 2010 572 599